Tagrisso Tablet, Film Coated
Product Images NDC 0310-1349

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tagrisso (NDC 0310-1349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tagrisso 40 mg Tablet Bottle Label

isso® griss Ta (osimertinib) tablets - NDG 0310-1349-30 30 Tablets - Rx only - Manufactured for AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850 by AstraZeneca AB, SE-151 85 Sodartaf, Sweden - Product of Switzerland - GTIN 00303101349307.*

FDA Label Image

Tagrisso 80 mg Tablet Bottle Label

The text describes a medicine named Tagrisso, which comes in tablets of 80mg each, with a package of 30 tablets. It provides the NDC code (0310-1350-30), the manufacturer (AstraZeneca AB, based in Sweden) and the product's country of origin (Switzerland). The medicine is prescription-only (Rx only).*

FDA Label Image

Chem_structure (Chemical Structure)

FDA Label Image

Figure 1 Adaura

FDA Label Image

Figure 2

This text provides data on the probability of progression-free survival for two different treatments (TAGRISSO and EGFRTKI) at various time points (0, 3, 6, 9, 12, 15, 18, 21, 24, 27 months) after randomization. The numbers in the table represent the percentage of patients who had progression-free survival with each treatment at each time point. The symbol "+" indicates censored patients.*

FDA Label Image

Figure 3

This appears to be survival analysis data represented in a table format. The table shows the probability of overall survival for patients taking either TAGRISSO or EGFRTKI. The time from randomization (in months) is plotted on the x-axis and the number of patients is plotted on the y-axis. The table also shows the number of patients at risk for each medication at each time interval.*

FDA Label Image

Figure 4

This is a graph showing the Probability of Progression-free survival for two treatments, TAGRISSO and Chemotherapy, over the course of 18 months. The X-axis shows the time since randomization in months. The Y-axis represents the Probability of Progression-free survival. The graph shows that TAGRISSO has a higher Probability of Progression-free survival than Chemotherapy throughout the 18 months. The numbers at the base of the figure indicate the number of subjects at risk for each treatment group.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.